Antithrombin Replacement During Extracorporeal Membrane Oxygenation

Artificial Organs

Volumn 35, Issue 11, 2011, Pages 1024-1028

  Niebler, Robert A ^a   Christensen, Melissa ^a   Berens, Richard ^a   Wellner, Heidi ^b   Mikhailov, Theresa ^a   Tweddell, James S ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Children's Hospital of Wisconsin   (United States)

Author keywords

Antithrombin III; Extracorporeal membrane oxygenation; Hemorrhage; Heparin; Pediatrics

Indexed keywords

BLOOD; OXYGENATION; PEDIATRICS; POLYSACCHARIDES;

ACTIVATED CLOTTING TIME; ACTIVITY LEVELS; ANTI-COAGULATION; ANTITHROMBIN; ANTITHROMBIN III; BLEEDINGS; CHEST TUBES; DRIP RATE; EXTRACORPOREAL MEMBRANE OXYGENATION; HAEMORRAGE;

RESPIRATORY THERAPY;

ANTITHROMBIN III; HEPARIN; RECOMBINANT ANTITHROMBIN III;

ACTIVATED CLOTTING TIME; ADOLESCENT; ADULT; ANTICOAGULANT THERAPY; ANTITHROMBIN REPLACEMENT; ARTICLE; BLOOD CLOTTING TIME; BRAIN HEMORRHAGE; CARDIOPULMONARY BYPASS; CHILD; DRUG DOSE TITRATION; EXTRACORPOREAL OXYGENATION; FEMALE; FORWARD HEART FAILURE; HUMAN; INFANT; MALE; MEDICAL RECORD REVIEW; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; RESUSCITATION; SCHOOL CHILD; SUBSTITUTION THERAPY;

EID: 81855166260     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2011.01384.x     Document Type: Article

References (19)

1. Chung DH, Zwischenberger JB. Emergencies during extracorporeal membrane oxygenation and their management. In: Zwischenberger JB, Steinhorn RH, Bartlett RH, eds. ECMO Extracorporeal Cardiopulmonary Support in Critical Care, Second Edition, Ann Arbor, MI: Extracorporeal Life Support Orginization, 2000;269-94.
2. Graves DF, Chernin JM, Kurusz M, Zwischenberger JB. Anticoagulation practices during neonatal extracorporeal membrane oxygenation: survey results. Perfusion 1996;11:461-6.
3. Oliver WC. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009;13:154-75.
4. Rosenberg RD. Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med 1989;87:2S-9S.
5. Villaneuva GB, Danishefsky I. Evidence for a heparin-induced conformational change on antithrombin III. Biochem Biophys Res Commun 1977;74:803-9.
6. Urlesberger B, Zobel G, Zenz W, etal. Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants. J Pediatr 1996;129:264-8.
7. Agati S, Ciccarello G, Salvo D, Turla G, Undar A, Mignosa C. Use of a novel anticoagulation strategy during ECMO in a pediatric population: single-center experience. ASAIO J 2006;52:513-6.
8. Despotis GJ, Joist JH, Hogue CW, etal. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995;110:46-54.
9. Avidan MS, Levy JH, Scholz J, etal. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005;102:276-84.
10. Avidan MS, Levy JH, van Aken H, etal. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005;130:107-13.
11. Koster A, Chew D, Kuebler W, Habazettl H, Hetzer R, Kuppe H. High antithrombin III levels attenuate hemostatic activation and leukocyte activation during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2003;126:906-7.
12. Lemmer JH Jr, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002;123:213-7.
13. Andrew M, Paes B, Milner R, etal. Development of the human coagulation system in the full-term infant. Blood 1987;70:165-72.
14. Odegard KC, Zurakowski D, DiNardo JA, etal. Prospective longitudinal study of coagulation profiles in children with hypoplastic left heart syndrome from stage I through Fontan completion. J Thorac Cardiovasc Surg 2009;137:934-41.
15. Odegard KC, Zurakowski D, Hornykewycz S, etal. Evaluation of the coagulation system in children with two-ventricle congenital heart disease. Ann Thorac Surg 2007;83:1797-803.
16. Hakacova N, Laluhova-Striezencova Z, Zahorec M. Disturbances of coagulation in neonates with functionally univentricular physiology prior to the first stage of surgical reconstruction. Cardiol Young 2008;18:397-401.
17. Bassler D, Millar D, Schmidt B. Antithrombin for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2006;(4):CD005383.
18. Schmidt B, Gillie P, Mitchell L, Andrew M, Caco C, Roberts R. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998;158:470-6.
19. Fulia F, Cordaro S, Meo P, etal. Can the administration of antithrombin III decrease the risk of cerebral hemorrhage in premature infants? Biol Neonate 2003;83:1-5.